Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Deep Sequencing Is a Widely Applicable Tool for Relapse Prediction in Acute Myeloid Leukemia with Mutated NPM1

Sofie Johansson Alm, Gustav Orrsjö, Giti Shah Barkhordar, Anna Rehammar, Erik Delsing Malmberg, Per-Ola Andersson, Mats L. Brune, Hege Kristin Gravdahl Garelius, Mats Hardling, Lars Palmqvist, Linda Fogelstrand

Blood (2023) 142 (Supplement 1): 2963.

https://doi.org/10.1182/blood-2023-173497

Published: 2023

Journal Articles

Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients

Robert Zeiser, MD, Andreas Burchert, MD, Claudia Lengerke, MD, Mareike Verbeek, Kristina Maas-Bauer, MD, Stephan Metzelder, MD, Silvia Spoerl, MD, Markus Ditschkowski, MD, Matyas Ecsedi, MD, Katja Sockel, MD, Francis Ayuk, MD, Salem Ajib, MD, Flore Sicre de Fontbrune, MD, Il-Kang Na, MD, Livius Penter, MD, Udo Holtick, MD PhD, Dominik Wolf, MD, Esther Schuler, MD, Everett Meyer, MD PhD, Petya Apostolova, MD, Hartmut Bertz, MD, Reinhard Marks, Michael Luebbert, MD, Ralph M. Waesch, MD PhD, Christof Scheid, MD PhD, Friedrich Stölzel, MD, Rainer Ordemann, MD, Gesine Bug, MD, Guido Kobbe, MD, Robert Negrin, MD, Mats L Brune, Alexandros Spyridonidis, Annette Schmitt-Graeff, MD, Walter van der Velden, MD, Gerwin Huls, MD PhD, Stephan Mielke, MD, Goetz Ulrich Grigoleit, MD, Jurgen Kuball, MDPhD, Ryan P Flynn, PhD, Gabriele Ihorst, PhD, Jing Du, Bruce R. Blazar, MD, Renate Arnold, MD, Nicolaus Kröger, MD, Joerg Halter, MD, Gerard Socie, Dietrich Beelen, MD, Christian Peschel, MD, Andreas Neubauer, MD, Juergen Finke, MD, Justus Duyster, MD PhD, Nikolas von Bubnoff, MD

Blood (2015) 126 (23): 858.

https://doi.org/10.1182/blood.V126.23.858.858

Published: 2015

Journal Articles

Natural Killer Cell Expression of Natural Cytotoxicity Receptors Determines Relapse Risk in Elderly Patients with Acute Myeloid Leukemia Receiving Immunotherapy with Histamine Dihydrochloride and Interleukin-2

Anna Martner, PhD, Anna Rydström, PhD, Rebecca E Riise, Johan Aurelius, PhD, Mats L Brune, MD, Robin Foa, MD, Kristoffer Hellstrand, MD, Fredrik B Thorén, PhD

Blood (2014) 124 (21): 3680.

https://doi.org/10.1182/blood.V124.21.3680.3680

Published: 2014

Journal Articles

Alkylator-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Lymphoma: A Registry Study Comparing Thiotepa-, Busulfan-, Melphalan- and Treosulfan-Containing Regimens On Behalf of the EBMT Lymphoma Working Party

Peter Dreger, MD, Herve Finel, Renato Fanin, MD, Paolo Corradini, MD, Michele Falda, MD, Jürgen Finke, MD, William Arcese, MD, Piero Galieni, MD, Luca Castagna, MD, Domenico Russo, Mats L Brune, Rosanna Scimè, MD, Enrico Maria Pogliani, MD, Fabio Benedetti, MD, Norbert Schmitz, MD, Ariane Boumendil

Blood (2012) 120 (21): 2033.

https://doi.org/10.1182/blood.V120.21.2033.2033

Published: 2012

Journal Articles

Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT

Blood (2012) 120 (21): 1975.

https://doi.org/10.1182/blood.V120.21.1975.1975

Published: 2012

Journal Articles

Proportion of Adult AML Patient Population Receiving Allogeneic Stem Cell Transplantation and Long-Term Outcome: Real World Data From the Swedish National Acute Leukemia Registry.

Gunnar Juliusson, Lars Möllgård, Sören Lehmann, MD, PhD, Åsa Rangert Derolf, M.D., Ulf Tidefelt, MD, PhD, Dick Stockelberg, MD, PhD, Mats L Brune, Vladimir Lazarevic, Petar Antunovic, Anders Wahlin, Martin Hoglund, MD, PhD

Blood (2009) 114 (22): 2289.

https://doi.org/10.1182/blood.V114.22.2289.2289

Published: 2009

Journal Articles

Allogeneic Stem Cell Transplantation After Reduced Intensity Conditioning (RIC-allo) in Patients with Relapsed or Refractory Hodgkin's Lymphoma (HL). Final Analysis of the HDR-Allo Protocol – A Prospective Clinical Trial by the Grupo Español de Linfomas / Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).

Anna Sureda, Carme Canals, Reyes Arranz, Dolores Caballero, Josep Maria Ribera, Mats L Brune, Jakob R. Passweg, Joan Besalduch, Rafael F Duarte, Angel Leon, Maria Jesus Pascual, Norbert Schmitz

Blood (2009) 114 (22): 658.

https://doi.org/10.1182/blood.V114.22.658.658

Published: 2009

Journal Articles

Comparison of Busulfan and Cyclophosphamide (Bu-Cy)-Based Standard Myeloablative Conditioning (MAC) Vs. Fludarabine and Busulfan (Flu-Bu)-Based Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR1) Aged >40 Years: a Retrospective Analysis From the Acute Leukemia Working Party of EBMT.

Mohamad Mohty, MD, PhD, Myriam Labopin, Gerard Socié, MD, PhD, Noel-Jean Milpied, MD, Michel Attal, MD, Didier Blaise, MD, Olle Ringden, MD, Paul Brown, Brinch Lorentz, Mats L Brune, Rose-Marie Hamladji, Rafael F Duarte, Arnon Nagler, Vanderson Rocha, MD, PhD

Blood (2009) 114 (22): 3364.

https://doi.org/10.1182/blood.V114.22.3364.3364

Published: 2009

Journal Articles

Fludarabine, Cyclophosphamide, Anti-Thymocyte Globulin, with or without “ 2Gy TBI, for Alternative Donor Transplants in Acquired Aplastic Anemia (SAA): A Report From the EBMT-SAA Working Party.

Andrea Bacigalupo, Gerard Socie', Edoardo Lanino, Arcangelo Prete, Franco Locatelli, Anna Locasciulli, Simone Cesaro, Avicahi Shimoni, Judith Marsh, Mats L Brune, Jakob R. Passweg

Blood (2009) 114 (22): 1207.

https://doi.org/10.1182/blood.V114.22.1207.1207

Published: 2009

Journal Articles

Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)

Blood (2008) 112 (11): 3303.

https://doi.org/10.1182/blood.V112.11.3303.3303

Published: 2008

Journal Articles

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Assessment of Consistency and Robustness of Treatment Benefit for Patients in First Complete Remission.

Marc E Buyse, ScD, Pierre Squifflet, MSc, Jacob M Rowe, MD, John K Whisnant, MD, Dileep Bhagwat, PhD, MBA, Stephane E Allard, MD, Kristoffer Hellstrand, MD, PhD, Mats L Brune, MD

Blood (2008) 112 (11): 1948.

https://doi.org/10.1182/blood.V112.11.1948.1948

Published: 2008

Journal Articles

CD16/FcãRIII Antigen Expression Determines Oxidative Sensitivity in Cytotoxic Lymphocyte Subsets

Johan Aurelius, Galia Askarieh, Ana I. Romero, PhD, Fredrik B. Thorén, PhD, Mats L Brune, MD, Kristoffer Hellstrand, M.D., PhD

Blood (2008) 112 (11): 4921.

https://doi.org/10.1182/blood.V112.11.4921.4921

Published: 2008

Journal Articles

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.

Mats L. Brune, MD, Jacob M. Rowe, MD, Jeff Szer, MD, Donna E. Hogge, MD, John Catalano, MD, Elisabeth Wallhult, RN, Bo I. Nilsson, MD, Bengt Simonsson, MD, Ruth Spearing, MD, Stephane Allard, MD, Edward A. Stadtmauer, MD, Kristoffer Hellstrand, MD

Blood (2007) 110 (11): 1846.

https://doi.org/10.1182/blood.V110.11.1846.1846

Published: 2007

Journal Articles

Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia.

Elisabeth Wallhult, RN, John Whisnant, MD, Jacob M. Rowe, MD, Jeff Szer, MD, Dileep Bhagwat, PhD, Kristoffer Hellstrand, MD, Bo I. Nilsson, MD, Mats L. Brune, MD

Blood (2007) 110 (11): 4381.

https://doi.org/10.1182/blood.V110.11.4381.4381

Published: 2007

Journal Articles

Application of Risk-Adapted Therapy for Acute Myeloid Leukemia to a Population. Effects of Stem Cell Transplantation on Outcome.

Anders Wahlin, M.D., Ph.D, Mats L. Brune, M.D., Ph.D., Rolf Billstrom, M.D., Ph.D.

Blood (2004) 104 (11): 4449.

https://doi.org/10.1182/blood.V104.11.4449.4449

Published: 2004

NARROW

Deep Sequencing Is a Widely Applicable Tool for Relapse Prediction in Acute Myeloid Leukemia with Mutated NPM1

Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients

Natural Killer Cell Expression of Natural Cytotoxicity Receptors Determines Relapse Risk in Elderly Patients with Acute Myeloid Leukemia Receiving Immunotherapy with Histamine Dihydrochloride and Interleukin-2

Alkylator-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Lymphoma: A Registry Study Comparing Thiotepa-, Busulfan-, Melphalan- and Treosulfan-Containing Regimens On Behalf of the EBMT Lymphoma Working Party

Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT

Proportion of Adult AML Patient Population Receiving Allogeneic Stem Cell Transplantation and Long-Term Outcome: Real World Data From the Swedish National Acute Leukemia Registry.

Fludarabine, Cyclophosphamide, Anti-Thymocyte Globulin, with or without “ 2Gy TBI, for Alternative Donor Transplants in Acquired Aplastic Anemia (SAA): A Report From the EBMT-SAA Working Party.

Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Assessment of Consistency and Robustness of Treatment Benefit for Patients in First Complete Remission.

CD16/FcãRIII Antigen Expression Determines Oxidative Sensitivity in Cytotoxic Lymphocyte Subsets

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.

Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia.

Application of Risk-Adapted Therapy for Acute Myeloid Leukemia to a Population. Effects of Stem Cell Transplantation on Outcome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only